
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences Inc. has demonstrated significant advancements in its lead CAR-NK therapy, SENTI-202, showing a complete response rate of 42% in its phase I study for relapsed/refractory AML, indicating promising efficacy and potential for durable responses in a broad patient population. The receipt of Regenerative Medicine Advanced Therapy (RMAT) designation positions the company favorably for streamlined FDA engagement as it prepares for pivotal trials scheduled to begin in 2026, enhancing its regulatory outlook. Overall, the increase in the probability of success for its programs, coupled with the encouraging clinical data, contributes to a positive outlook for Senti Biosciences's stock.
Bears say
Senti Biosciences is facing potential downward revisions to its risk-adjusted projections and price target, indicating a concerning outlook for its financial health. These anticipated adjustments suggest that the company's current and future financial performance may not meet market expectations. Additionally, the repeated emphasis on possible downward revisions highlights significant uncertainty surrounding Senti Biosciences' product developments and their respective impacts on revenue generation.
This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares